Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a cas...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.621591/full |
| _version_ | 1819158094263877632 |
|---|---|
| author | Paul V. Viscuse Mario L. Marques-Piubelli Meghan M. Heberton Edwin Roger Parra Amishi Y. Shah Arlene Siefker-Radtke Jianjun Gao Sangeeta Goswami Doina Ivan Jonathan L. Curry Jonathan L. Curry Matthew T. Campbell |
| author_facet | Paul V. Viscuse Mario L. Marques-Piubelli Meghan M. Heberton Edwin Roger Parra Amishi Y. Shah Arlene Siefker-Radtke Jianjun Gao Sangeeta Goswami Doina Ivan Jonathan L. Curry Jonathan L. Curry Matthew T. Campbell |
| author_sort | Paul V. Viscuse |
| collection | DOAJ |
| description | Enfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology. |
| first_indexed | 2024-12-22T16:19:11Z |
| format | Article |
| id | doaj.art-55a10ccbe61c41a892852b9f573c314e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T16:19:11Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-55a10ccbe61c41a892852b9f573c314e2022-12-21T18:20:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.621591621591Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity ReactionPaul V. Viscuse0Mario L. Marques-Piubelli1Meghan M. Heberton2Edwin Roger Parra3Amishi Y. Shah4Arlene Siefker-Radtke5Jianjun Gao6Sangeeta Goswami7Doina Ivan8Jonathan L. Curry9Jonathan L. Curry10Matthew T. Campbell11Division of Cancer Medicine-Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesEnfortumab vedotin is a Nectin-4 directed antibody-drug conjugate approved in metastatic urothelial carcinoma following progression on a platinum-containing chemotherapy and immune checkpoint blockade. On-target dermatologic toxicity may occur from Nectin-4 expression in the skin. We highlight a case of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis following enfortumab infusions that was ultimately fatal. The second case describes an erythema multiforme-like rash with interface dermatitis related to enfortumab. Dermatologic findings, immunohistochemistry studies, and immune profiling are detailed. These cases demonstrate the potentially catastrophic outcomes in some patients treated with enfortumab. Patients must be monitored for cutaneous toxicities with early involvement of dermatology and dermatopathology.https://www.frontiersin.org/articles/10.3389/fonc.2021.621591/fullbladder cancerenfortumab vedotinSJS/TENurothelial canceradverse (side) effectserythema multiform |
| spellingShingle | Paul V. Viscuse Mario L. Marques-Piubelli Meghan M. Heberton Edwin Roger Parra Amishi Y. Shah Arlene Siefker-Radtke Jianjun Gao Sangeeta Goswami Doina Ivan Jonathan L. Curry Jonathan L. Curry Matthew T. Campbell Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction Frontiers in Oncology bladder cancer enfortumab vedotin SJS/TEN urothelial cancer adverse (side) effects erythema multiform |
| title | Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction |
| title_full | Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction |
| title_fullStr | Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction |
| title_full_unstemmed | Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction |
| title_short | Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction |
| title_sort | case report enfortumab vedotin for metastatic urothelial carcinoma a case series on the clinical and histopathologic spectrum of adverse cutaneous reactions from fatal stevens johnson syndrome toxic epidermal necrolysis to dermal hypersensitivity reaction |
| topic | bladder cancer enfortumab vedotin SJS/TEN urothelial cancer adverse (side) effects erythema multiform |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.621591/full |
| work_keys_str_mv | AT paulvviscuse casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT mariolmarquespiubelli casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT meghanmheberton casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT edwinrogerparra casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT amishiyshah casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT arlenesiefkerradtke casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT jianjungao casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT sangeetagoswami casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT doinaivan casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT jonathanlcurry casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT jonathanlcurry casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction AT matthewtcampbell casereportenfortumabvedotinformetastaticurothelialcarcinomaacaseseriesontheclinicalandhistopathologicspectrumofadversecutaneousreactionsfromfatalstevensjohnsonsyndrometoxicepidermalnecrolysistodermalhypersensitivityreaction |